-
Mashup Score: 2
Liso-cel received regulatory acceptances from the US FDA and the Ministry of Health, Labour and Welfare in Japan for FL.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 0Bispecific Lentiviral Anti-CD20/Anti-CD19 CAR T-Cells for R/R MCL - 4 month(s) ago
During the 2023 ASH Annual Meeting in San Diego, Nirav N Shah, MD, discussed the efficacy of dual-targeted lentiviral anti-CD20/anti-CD19 (LV20.19) CAR T-cells with an adaptive manufacturing process among patients with relapsed/refractory mantle cell lymphoma.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
Kami Maddocks, MD, reviews new possibilities and the latest advances in the treatment of patients with mantle cell lymphoma with Jia Ruan, MD, PhD, and Krish Patel, MD.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
Investigators report high response rates with pirtobrutinib in those with mantle cell lymphoma and high-risk disease features in the phase 1/2 BRUIN trial.
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1
An abstract is unavailable.
Source: journals.lww.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4Ibrutinib Combined with Bortezomib Shows ‘Durable Efficacy’ in MCL - 7 month(s) ago
Ibrutinib combined with bortezomib showed “durable efficacy” and safety in patients with relapsed or refractory mantle cell lymphoma (MCL), according to a study published in eClinicalMedicine. The phase I/II trial, led by Urban Novak, MD, University Hospital of Bern in Switzerland, established the recommended phase II dose of ibrutinib combined with bortezomib and assessed its efficacy in patients with relapsed or refractory MCL. The study included ibrutinib-naïve and bortez omib-naïve patients with
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 4Brexu-cel Has ‘Substantial’ Benefit Over SOC in Relapsed or Refractory MCL Post-BTKi Therapy - 7 month(s) ago
Home > Mantle Cell Lymphoma > Brexu-cel Has ‘Substantial’ Benefit Over SOC in Relapsed or Refractory MCL Post-BTKi Therapy Researchers demonstrated a “substantial treatment benefit” in an indirect treatment comparison of brexucabtagene autoleucel (brexu-cel) with the standard of care in patients with relapsed or refractory mantle cell lymphoma (MCL) after Bruton tyrosine kinase inhibitor (BTKi) exposure, according to a study published in Leukemia and Lymphoma. The study, led by Georg Hess, MD, of the
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 0Addition of Venetoclax to Lenalidomide and Rituximab Therapy for Patients With Previously Untreated MCL - 7 month(s) ago
Kami J. Maddocks, MD, discusses results from a single-arm study on the addition of venetoclax to a lenalidomide and rituximab regimen for patients with previously untreated mantle cell lymphoma.
Source: www.hmpgloballearningnetwork.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In this video, Kami J Maddocks, MD, discusses the results of a multicenter single-arm study that explored the addition of #venetoclax to #lenalidomide and #rituximab treatment for patients with previously untreated #MCL. Learn more: https://t.co/sqXKHEqdHY @kmaddmd #MedTwitter https://t.co/bYfGsyhWKm
-
-
Mashup Score: 0Exploring the Design of the ECOG-ACRIN E1411 Trial in MCL - 7 month(s) ago
Mitchell Smith, MD, PhD, discusses the ECOG-ACRIN E1411 trial among patients with previously untreated mantle cell lymphoma.
Source: www.targetedonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Allogeneic Stem Cell Transplantation Demonstrates Lasting Remissions Among Patients With MCL, Including With TP53 Mutations - 7 month(s) ago
Allogeneic stem cell transplantation demonstrated long-term remissions among patients with mantle cell lymphoma, including patients with TP53-mutated disease, according to an extended follow-up study.
Source: www.hmpgloballearningnetwork.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
Liso-cel received regulatory acceptances from the @US_FDA and the Ministry of Health, Labour and Welfare in Japan for #MCL and follicular lymphoma. 📰 Read more: https://t.co/JezRlypse9 https://t.co/53fCfAUBh3